BioVerity Press Release

9th July, 2014
FOR IMMEDIATE RELEASE
ANTI-AGING RESEARCH TO BE COMMERCIALIZED
Toronto, Canada

BioVerity Inc. is pleased to announce an exclusive collaborative research and license agreement with McMaster University in Hamilton, ON, to commercialize a complex dietary supplement aimed to ameliorate processes associated with aging. The formulation was developed by three McMaster University scientists – Dr. David Rollo, Dr. Douglas Boreham and Dr. Jennifer Lemon.

“I kept on hearing about McMaster’s research on aging in the media,” said Max Carbone, CEO of Bioverity. “After a segment on the national news in 2012(1) I talked to my father, a pioneering wellness physician, to ask him what he thought. He agreed with what he heard and encouraged me to speak with the researchers. A year later with key partners Bioverity was founded.”

For over a decade, the McMaster team has worked on optimizing a formulation of food-based ingredients that synergistically address five key aspects associated with aging: oxidative stress, insulin resistance, mitochondrial activity, inflammation, and cellular membrane integrity. Results from research with mice and insects obtained remarkable results. Both insects and mice given the formula had significantly increased longevity (27% in a mouse model of accelerated aging(2)) and mice also maintained youthful levels of learning(3), physical activity and appearance into advanced old age(4). In fact, increases in mouse “healthspan” meant that animals remained youthful for a greater proportion of their lives.

“The formulation has years of science behind it,” said Joe Castaldi, VP Bioverity. “We plan on working with the McMaster team to pursue the full potential of the formula.”

This license agreement enables BioVerity Inc. to quickly move forward with the global commercialization of the complex dietary formula under the brand name BioVerity. Although the formulation consists of compounds known and tested to be safe for human consumption, the company is in the process of raising capital to complete human clinical trials to further validate these health claims in the coming months. Bioverity has been in discussions with several groups to establish an initial U.S. test market, with a subsequent rollout in both Canada and the United States.

BioVerity Inc. was established in 2013 to commercialize McMaster’s evidence-based scientific learning and intellectual property on complex dietary supplements. The company is based in Toronto and is led by: Max Carbone, CEO, Joseph Castaldi, VP, and Dr. Nicholas Rupcich, Chief Science Officer.

To contact BioVerity Inc. please call 1-800-382-1959.


(1) CBC News. Aging slowed in mice with supplement mix. 2 January 2012.
(2) Lyn J, Aksenov V, LeBlanc Z, and Rollo CD.* 2012. Life history features and aging rates: Insights from intra-specific patterns in the cricket Acheta domesticus. Evol. Biol. 39: 371-387. (IF: 3.61)
(3) Aksenov V, Khanna P, Long J, Liu J, Szechtman H, Matravadia S, Rollo CD.* 2012. A complex dietary supplement improves spatial learning, increases brain size and improves mitochondrial activity in aging mice. AGE: DOI: 10.1007/s11357-011-9325-2 (Impact Factor (IF): 6.28.
(4) Lemon, J.A., Boreham, D.R., Rollo, C.D. 2003. A dietary supplement abolishes age-related cognitive decline in transgenic mice expressing elevated free radical processes. Exp. Biol. Med. 228:800-810.

Impact of a Complex Nutraceutical Supplement on Primary Tumour Formation

Aksenov V, Boreham DR, Rollo CD.

Mutagenesis 2014 May; 29(3):177-87.

Excerpt: A complex dietary supplement designed to impact multiple mechanisms associated with aging and cancer reduced overall tumorigenesis in cancer-prone heterozygous Trp53+/– mice by ~30% (P < 0.018). Carcinomas were reduced by 67% (P < 0.006). Remarkably, metastasis (a leading cause of cancer mortality) was undetectable in treated animals (P < 0.004), and the occurrence of multiple primary tumours was reduced by 74% (P < 0.012). Reduction of pulmonary adenocarcinoma by 62% (P < 0.021) was of particular note given that lung cancer is the second leading cause of death in humans. Tumours showed pronounced age-related expression in untreated animals older than 600 days. Benefits of treatment only emerged in these later ages, suggesting that the supplement acted on mechanisms common to aging and cancer. The supplement was administered daily on bagel bits that were usually eaten within minutes by the mice. Although longevity was not statistically different between treatments, longevity was strongly related to the compliance of mice in eating the supplement. Linear regression revealed a strong positive relationship between the proportion of supplement eaten and the longevity of mice within the treatment group (P < 0.0001). Read the Full Article